Next-Gen Formats & Emerging Modalities
- Are multispecific and dual-payload formats solving real clinical problems, or adding complexity ahead of the evidence?
- The expanding definition of “bioconjugate” where ADCs end, and a broader modality class begins
- What the field can and cannot carry over from ADCs as it moves into oligonucleotides, peptides, and radioconjugates
- The strategic case for diversifying beyond oncology: clinical opportunity versus development risk
- How novel formats reshape expectations for manufacturing, analytics, and regulatory pathways
- Which next-generation formats are most likely to reach regulatory approval and move into the clinic
- Partnership and platform models driving emerging-modality programs